|
市場調查報告書
製藥企業分析報告：Novartis
Novartis: Pipeline, Products, Performance, Potential
|
本報告已在2011年06月06日停止出版。
更改為出版
Novartis:
Pipeline * Products * Performance * Potential
出版日期 : 2011年03月
商品編碼: 196743
提供醫療儀器、藥品相關情報，獲得全球高度評價的英國市調公司 Espicom Business Intelligence，調查分析了製藥企業Navartis後，出版了一本綜合報告書"Novartis: Performance, Products, Pipeline and Potential"。
報告書內容包括：企業策略、產品組合、財務成績、2000年至2010年銷售資料等等，內容綱要摘記如下：
摘要
- 摘要
- 2005年財務成績
- 企業策略
- 產品、研發概要
- 結論
產品組合、研發
- 心臟血管、代謝系統
- 癌症
- 風濕、骨骼疾病、荷爾蒙補充療法（HRT）
- 中樞神經
- 呼吸器官、皮膚科
- 自我免疫、移植
- 眼科
- 胃腸
- 感染症
附錄
- 財務成績
- 主要合作
- 基礎建設
- 相關企業、合作夥伴
- 產品索引
Abstract
Following the merger of Ciba and Sandoz, the spin-off of the Agribusiness
sector and the sale of the remaining activities of the Industry division,
Novartis has become a leading company in the life sciences field and has
operations in approximately 140 countries worldwide. Novartis is currently
organised into the four divisions of Pharmaceuticals, Consumer Health, Sandoz,
and Vaccines & Diagnostics, created following the acquisition of Chiron
Corporation. Within Pharmaceuticals, the company' s current growth drivers
include Diovan (valsartan), Glivec/Gleevec (imatinib), Femara (letrozole) and
Zometa (zoledronate).
Novartis delivered a steady performance in 2008. Operating income was down by
30.1 per cent and net income down by 31.2 per cent. Within Pharmaceuticals,
Novartis' strategic products such as Diovan (valsartan), Glivec/Gleevec
(imatinib), Femara (letrozole) and Zometa (zoledronate) continued to perform
well, while Consumer Health benefited from the North American OTC business of
Bristol-Myers Squibb which was acquired in 2005. Sales at Sandoz increased by
20.3 per cent due to the continued effects of the Hexal and Eon Labs
acquisitions, which have made it a world leader in generics.
In the longer term, as a research-intensive company which has benefited from
the Chiron acquisition, Novartis has a strong pharmaceutical pipeline with a
total of 139 compounds under development. With a number of projects in
late-stage development, of particular note is fingolimod, which is under Phase
III development for multiple sclerosis.
This new strategic analysis report Novartis: Pipeline - Products -
Performance - Potential, provides a complete and critical review of the
company and includes unique and independent assessments and forecasts of key
products. Buyers of the web edition receive online access for one year via an
easy-to-use interface with fast navigation and a full text search facility.
All formats are the same price.
Table of Contents
- Latest Results
- EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance 2008
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Research and Development
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Conclusions
- THERA PEUTI C AR EA FOCUS
- R&D PIPELINE
- CARDIOVASCULAR AND METABOLIS
- Marketed Products
- Diovan/Co-Diovan
- Exforge
- Galvus
- Lescol
- Lotrel
- Rasilez/Tekturna
- Trazec
- R&D Projects
- Canakinumab
- HGH191
- LCI699
- LCZ696
- SBR759
- Tekturna FDC
- VNP489
- Growth Forecast
- ONCOLOGY/HAEMATO LOGY
- Marketed Products
- Exjade
- Femara
- Glivec/Gleevec
- Sandostatin
- Tasigna
- Zometa
- Others
- R&D Projects
- AEE788
- Affinitor
- ASA404
- AT9311
- AUY922
- BEZ235
- BHQ880
- Gimatecan (LBQ707)
- HCD122
- LBH589
- LBQ707
- LBY135
- Midostaurin
- Opaxio (formerly known as Xyotax)
- Pasireotide (SOM230)
- Patupilone
- RAF265
- TKI258
- Growth Forecast
- NEUROS CIENCE
- Marketed Products
- Comtan
- Exelon
- Extavia
- Ritalin/Focalin
- Stalevo
- Trileptal
- Others
- R&D Projects
- AFQ056
- AQW051
- ATI355
- BAF312
- BGG492
- CAD106
- Fingolimod
- KRP203
- SAB378
- Valdoxan
- Growth Forecast
- OPHTHALMICS/DERMATOLOGY/GASTROINTESTINAL/UROLOGY
- Marketed Products
- Elidel
- Lamisil
- Lucentis
- Zelnorm/Zelmac
- Others
- R&D Projects
- AIN457
- BCT194
- Canakinumab
- DNK333
- Rebamipide
- SAD448
- Y39983
- Growth Forecast
- Ophthalmics
- Dermatology
- Gastrointestinal
- Urology
- INFECTIO US DISEASES/TRANSPLANTATION/IMMUNOLOGY
- Marketed Products
- Certican
- Coartem
- Ixiaro
- Sandimmun/Neoral
- Sebivo/Tyzeka
- Others
- Celtura
- R&D Projects
- AEB071
- Aflunov
- AHT956
- Albuferon (ABF656)
- MenB
- Menveo
- Mycograb
- NIM811
- RSV604
- Tifacogin
- Valopicitabine
- Valtorcitabine
- Growth Forecast
- Infectious Diseases
- Infectious Diseases
- Transplantation/Immunology
- ARTHRITIS /BONE
- Marketed Products
- Aclasta/Reclast
- Miacalcic/Miacalcin
- Voltaren/Cataflam
- Others
- R&D Projects
- ATF936
- Canakinumab
- QAL964
- PTH (1-34)
- Growth Forecast
- RESPIRATOR Y
- Marketed Products
- R&D Projects
- Canakinumab
- Indacaterol
- NIC002
- NVA237
- QAE397
- QAT370
- QAU145
- QAX028
- QAX576
- QAX935
- VAK694
- Growth Forecast
- APPENDIX 1 - FINANCIA L PERFOR MANCE
- APPENDIX 2 - KEY AGREEMENTS
- Ablynx
- Alfacell Corporation
- Allergan
- Alnylam Pharmaceuticals
- AlphaVax Inc.
- Anadys Pharmaceuticals Inc.
- Antisoma plc
- APT Pharmaceuticals
- Ardana plc
- Arrow Therapeutics Ltd.
- Ascent Therapeutics Inc.
- Astex Therapeutics Ltd.
- AstraZeneca
- Avanir Pharmaceuticals Corporation
- Avalon Pharmaceuticals
- Avila Therapeutics
- Bausch & Lomb Inc.
- Beijing Med-Pharm Corp
- Broad Institute / Harvard University
- Bayer Schering Pharma
- Biovail Corporation
- BTG
- Celgene Corporation
- Cell Therapeutics Inc.
- Cerimon Pharmaceuticals Inc.
- Clinical Data Inc.
- CombinatoRx Inc.
- Conor Medsystems Inc.
- Cytos Biotechnology AG
- Cytopia Ltd.
- Dynavax Technologies Corp
- Elan Corporation plc
- Elixir Medical Co
- Elixir Pharmaceuticals
- Emisphere Technologies Inc.
- Endo Pharmaceuticals
- Epistem Holdings PLC
- Evotec AG
- FORMA Therapeutics Inc.
- Galapagos NV
- Genelabs Technologies
- Genentech
- Gilead Sciences Inc.
- Human Genome Sciences (HGS)
- Idenix Pharmaceuticals Inc.
- Idera Pharmaceuticals Inc.
- Immusol Incorporated
- Infinity Pharmaceuticals Inc.
- Intercell AG
- IVAX Corporation
- Kyorin Pharmaceutical Co Ltd.
- Lonza Group Ltd.
- Meda AB
- Medarex Inc.
- Medivir AB
- Merck KGaA
- Merck & Co
- MicroDose Technologies Inc.
- Mitsubishi Tanabe Pharma Corporation
- Molecular Insight Pharmaceuticals Inc (MIP)
- MorphoSys AG
- MDRNA Inc.
- Nektar Therapeutics
- Nuevolution AS
- Portola Pharmaceuticals Inc.
- Proteon Therapeutics Inc.
- Ono Pharmaceutical Co Ltd.
- Opexa Therapeutics
- Orexo AB
- Orion Corporation
- Otsuka
- Peptimmune Inc.
- QLT Inc.
- Radius Health Inc.
- Regeneron Pharmaceuticals
- Reliant Pharmaceuticals Inc.
- Saegis Pharmaceuticals Inc.
- sanofi-aventis
- Senju Pharmaceutical Co Ltd.
- Servier
- Sigma-Tau
- SGX Pharmaceuticals Inc.
- SkyePharma PLC
- Takeda
- Tanox Biosystems Inc/Genentech Inc.
- UCB
- TopoTarget AS
- Valley Forge Pharmaceuticals Inc.
- Vectura Group plc/Arakis Ltd.
- Vernalis plc
- Xenon Pharmaceuticals Inc.
- XOMA Ltd.
- APPENDIX 3 - INFRASTR UCTURE
- Research and Development Facilities
- Manufacturing Facilities
- APPENDIX 4 - KEY PHARMACEUTICAL
- SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- APPENDIX 5 - PRO DUCT INDEX
INDEX OF TABLES:
- Principal Operating Results
- Capital Expenditure By Business Area
- Capital Expenditure By Geographical Area
- Research And Development Expenditure By Business Area
- Sales By Business Area
- Operating Income By Business Area
- Total Assets By Business Area
- Sales By Destination
- Operating Income By Geographical Area
- Total Assets By Destination
- Employees By Business Area (Year End)
- Employees By Geographical Area (Year End)
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Cardiovascular Products, 2008
- Major Oncology/Haematology Products, 2008
- Major Neuroscience Products, 2008
- Major ODGU Products, 2008
- Major IDTI Products, 2008
- Major Arthritis/Bone Products, 2008
- Major Respiratory Products, 2008
- Foradil Sales (2004A-2014E)
- Major Pharmaceutical Research & Development Facilities
- Major Pharmaceutical Production Facilities
INDEX OF CHARTS
- Capital Expenditure By Business Area, 2008
- Capital Expenditure By Geographical Area, 2008
- Research And Development Expenditure By Business Area, 2008
- Sales By Business Area
- Operating Income By Business Area
- Sales By Destination
- Operating Income by Geographic Area
- Employees By Business Area, 2008
- Employees By Geographical Area (Year End), 2008
- Forecast Sales of Major Products (2003A-2013E)
- Top Selling Products, 2008
- Diovan/Co-Diovan Product Sales (2004A-2014E)
- Exforge Sales (2007A - 2014E)
- Galvus Sales (2008E - 2014E)
- Lescol Sales (2004A-2014E)
- Lotrel Sales (2004A-2014E)
- Rasilez/Tekturna Sales (2007A - 2014E)
- Exjade Sales (2006A-2014E)
- Femara Sales (2004A-2014E)
- Glivec/Gleevec Sales (2004A-2014E)
- Sandostatin Sales (2004A-2014E)
- Tasigna Sales (2008E - 2014E)
- Zometa Sales (2004A-2014E)
- Stalevo/Comtan Sales (2005A-2014E)
- Exelon Sales (2004A-2014E)
- Extavia Sales (2009E-2014E)
- Ritalin Sales (2005A-2014E)
- Stalevo/Comtan Sales (2005A-2014E)
- Trileptal Sales (2004A-2014E)
- Fingolimod (2009E - 2014E)
- Valdoxan Sales (2009E-2014E)
- Elidel Sales (2004A-2014E)
- Lucentis Sales (2007A-2014E)
- Sandimmun/Neoral Sales (2004A-2014E)
- Tyzeka Sales (2008E-2014E)
- Aclasta/Reclast Sales (2006A-2014E)
- Miacalcic Sales (2004A-2014E)
- Voltaren Sales (2004A-2014E)
- Xolair Sales (2005A - 2014E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
|
